Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 4/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4955378 | 1.00 | CHRNA3 (0.41) | CHRNA3CHRNB4LTA4HCHRNB2CHRNA4 | |
| SCHEMBL7918053 | 0.92 | CYP2D6 (0.40) | CHRNA3CHRNB4LTA4H | |
| SCHEMBL7918057 | 0.92 | CYP2D6 (0.40) | CHRNA3CHRNB4LTA4H | |
| SCHEMBL18398793 | 0.91 | CHRNA3 (0.46) | CHRNA3CHRNB4LTA4HCHRNB2CHRNA4 | |
| SCHEMBL4470435 | 0.78 | — | — | |
| SCHEMBL3330177 | 0.78 | — | — | |
| SCHEMBL10273867 | 0.78 | — | — | |
| SCHEMBL10273866 | 0.78 | — | — | |
| SCHEMBL10273859 | 0.77 | CHRNA3 (0.44) | CHRNA3CHRNB4LTA4HCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL3442784 | 0.77 | CHRNA3 (0.44) | CHRNA3CHRNB4LTA4HCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | CHRNA3 2401/4885CHRNB4 1794/4885LTA4H 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.